As of November 7, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Olema Pharmaceuticals, Inc. The largest reported stake is Fmr LLC's, at 13.8%. 12 filings are on record since November 14, 2025 (Schedule 13G/A, August 6, 2026).
Sell to companies like Olema Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 5,946,981 · Sole dispositive: 0 · Shared dispositive: 5,946,981 · SCHEDULE 13D/A, 2026-10-16
- · Reporting person: Fmr LLC · Sole voting: 12,074,535 · Shared voting: 0 · Sole dispositive: 12,075,062 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-06
- · Reporting person: BlackRock, Inc. · Sole voting: 6,138,842 · Shared voting: 0 · Sole dispositive: 6,244,212 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-29
- · Holder: Bain Capital Life Sciences Opportunities IV, L.P. · Percent: 8.15% · SCHEDULE 13G/A
- · Holder: Janus Henderson Group Plc · Percent: 8.2% · SCHEDULE 13G/A
Olema Pharmaceuticals, Inc. has 12 Schedule 13D or 13G filings on record since 2025-11-14. 6 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 13.8% | 12,075,062 | SCHEDULE 13G/A, 2026-08-06 | 2026-06-30 |
| Biotechnology Value Fund L P | 9.8% | 5,946,981 | SCHEDULE 13D/A, 2026-10-16 | 2026-10-14 |
| Janus Henderson Group Plc | 8.2% | 7,108,488 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Bain Capital Life Sciences Opportunities IV, L.P. | 8.15% | 7,473,238 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| BlackRock, Inc. | 7.1% | 6,244,212 | SCHEDULE 13G/A, 2026-07-29 | 2026-06-30 |
| 5.1% | 4,461,949 | SCHEDULE 13G, 2026-03-20 | 2026-03-16 | |
| Deep Track Capital, LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
Holding shares or following this stake? See who's behind Olema Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Olema Pharmaceuticals, Inc. and the records around it.
Olema Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Bain Capital Life Sciences Opportunities IV, L.P. also filed stake reports on 1 other company: ADC Therapeutics SA (Oct 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026), Stoke Therapeutics, Inc. (Sep 2026)
Watch Olema Pharmaceuticals, Inc.
Get an email when Olema Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Olema Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Olema Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Olema Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 12,074,535 | 0 | 12,075,062 | 0 | SCHEDULE 13G/A, 2026-08-06 |
| Abigail P. Johnson | 0 | 0 | 12,075,062 | 0 | SCHEDULE 13G/A, 2026-08-06 |
| Biotechnology Value Fund L P | 0 | 5,946,981 | 0 | 5,946,981 | SCHEDULE 13D/A, 2026-10-16 |
| Bvf I Gp LLC | 0 | 5,946,981 | 0 | 5,946,981 | SCHEDULE 13D/A, 2026-10-16 |
| Biotechnology Value Fund Ii LP | 0 | 2,356,800 | 0 | 2,356,800 | SCHEDULE 13D/A, 2026-10-16 |
| Bvf Ii Gp LLC | 0 | 2,356,800 | 0 | 2,356,800 | SCHEDULE 13D/A, 2026-10-16 |
| Biotechnology Value Trading Fund OS LP | 0 | 347,970 | 0 | 347,970 | SCHEDULE 13D/A, 2026-10-16 |
| BVF Partners OS Ltd. | 0 | 347,970 | 0 | 347,970 | SCHEDULE 13D/A, 2026-10-16 |
| Bvf Gp Holdings LLC | 0 | 8,303,781 | 0 | 8,303,781 | SCHEDULE 13D/A, 2026-10-16 |
| Bvf Partners L P | 0 | 8,939,731 | 0 | 8,939,731 | SCHEDULE 13D/A, 2026-10-16 |
| Bvf Inc | 0 | 8,939,731 | 0 | 8,939,731 | SCHEDULE 13D/A, 2026-10-16 |
| Lampert Mark N | 0 | 8,939,731 | 0 | 8,939,731 | SCHEDULE 13D/A, 2026-10-16 |
| Hrustanovic Gorjan | 183,645 | 0 | 183,645 | 0 | SCHEDULE 13D/A, 2026-10-16 |
| BlackRock, Inc. | 6,138,842 | 0 | 6,244,212 | 0 | SCHEDULE 13G/A, 2026-07-29 |
The latest filing identifies Olema Pharmaceuticals, Inc. by CUSIP 68062P106 and gives its principal executive office as 780 BRANNAN STREET, SAN FRANCISCO, CA 94103 (SCHEDULE 13D/A, 2026-10-16).
Source of funds (Item 3)
Item 3 is hereby amended and restated to read as follows: The securities of the Issuer beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Accounts were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate cost basis of the 2,655,977 Shares directly beneficially owned by BVF is approximately $13,409,946, excluding brokerage commissions.Biotechnology Value Fund L P, SCHEDULE 13D/A, 2026-10-16
Purpose of Transaction (Item 4)
Biotechnology Value Fund L P
Item 4 is hereby amended to add the following: Effective October 14, 2026, Dr. Gorjan Hrustanovic resigned from the Board. Dr. Hrustanovic also resigned from the Compensation Committee of the Board and the Science and Technology Committee of the Board. Dr. Hrustanovic's resignation was not the result of any disagreement with the Issuer on any matter relating to the Issuer's operations, policies or practices.Item 4 of the SCHEDULE 13D/A filed 2026-10-16
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-14 | Janus Henderson Group Plc | 5.2% | SCHEDULE 13G |
| 2026-02-05 | Fmr LLC | 6.3% | SCHEDULE 13G |
| 2026-02-13 | Deep Track Capital, LP | 0% | SCHEDULE 13G/A |
| 2026-02-17 | Bain Capital Life Sciences Opportunities IV, L.P. | 9.99% | SCHEDULE 13G/A |
| 2026-02-17 | Janus Henderson Group Plc | 8.4% | SCHEDULE 13G/A |
| 2026-03-06 | Fmr LLC | 12.5% | SCHEDULE 13G/A |
| 2026-03-20 | Raymond Debbane | 5.1% | SCHEDULE 13G |
| 2026-05-15 | Bain Capital Life Sciences Opportunities IV, L.P. | 8.15% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 8.2% | SCHEDULE 13G/A |
| 2026-07-29 | BlackRock, Inc. | 7.1% | SCHEDULE 13G/A |
| 2026-08-06 | Fmr LLC | 13.8% | SCHEDULE 13G/A |
| 2026-10-16 | Biotechnology Value Fund L P | 9.8% | SCHEDULE 13D/A |
Questions about who owns Olema Pharmaceuticals, Inc.
Who owns Olema Pharmaceuticals, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Olema Pharmaceuticals, Inc.: Fmr LLC (13.8%, Schedule 13G/A, filed 2026-08-06), Biotechnology Value Fund L P (9.8%, Schedule 13D/A, filed 2026-10-16), Janus Henderson Group Plc (8.2%, Schedule 13G/A, filed 2026-05-15), Bain Capital Life Sciences Opportunities IV, L.P. (8.15%, Schedule 13G/A, filed 2026-05-15) and BlackRock, Inc. (7.1%, Schedule 13G/A, filed 2026-07-29); 1 more is listed above.
Who are the largest shareholders of Olema Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Olema Pharmaceuticals, Inc. on this page are Fmr LLC (13.8%), Biotechnology Value Fund L P (9.8%) and Janus Henderson Group Plc (8.2%).
When did Fmr LLC buy into Olema Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-02-05, reporting 6.3%; its latest, Schedule 13G/A filed 2026-08-06, reports 13.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Olema Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 15, 2026 | Leadership change: Gorjan Hrustanovic departs | — | Leadership changes | Source |
| August 13, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 29, 2026 | Leadership change: Prakash Raman appointed, Director | — | Leadership changes | Source |
| December 12, 2024 | Form D, private offering | $250M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Olema Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.